Angiofibroma: Causes, Symptoms, and Treatment in Children and Adults

Angiofibroma is a benign, vascular-rich fibrous lesion. Two clinically distinct groups are most commonly encountered in clinical practice: cutaneous angiofibromas (including a solitary "fibrous papule" on the face and multiple facial angiofibromas associated with tuberous sclerosis) and juvenile nasopharyngeal angiofibroma (JNA), a rare but locally aggressive skull base tumor in adolescent boys. Accurate differentiation determines examination, risks, and treatment. [1]

Cutaneous angiofibromas are dome-shaped, flesh-colored, pink papules on the face (most often the ala nasi/cheek). Solitary lesions are usually "cosmetic" and stable; multiple lesions in a child or young adult are an important marker of tuberous sclerosis and a reason to evaluate the skin, kidneys, and nervous system. Confirmation is by dermatoscopy/shave biopsy; treatment is often optional due to appearance. [2]

JNA is a different story: a highly vascular nasopharyngeal tumor in adolescents, presenting with nasal congestion and recurrent nosebleeds. Despite benign histology, the tumor grows into the nasal cavity, paranasal sinuses, and pterygopalatine fossa, can deform bones, and undermine the base of the skull, and therefore requires an active approach with surgery (usually endoscopic these days) and preoperative embolization. [3]

Below is a unified "roadmap" for both groups: epidemiology, causes and risk factors, pathogenesis, symptoms, classification, complications, when to see a doctor, diagnosis and differential diagnosis, followed by detailed treatment (including modern methods), prevention, prognosis, and FAQ. Tables will help both specialists and readers quickly navigate the process. [4]

Table 1. Two main "branches" of angiofibromas

Option	Who is sick?	Main manifestations	What decides fate
Cutaneous angiofibroma (fibrous papule or multiple facial angiofibromas)	Adolescents and adults; in tuberous sclerosis - children	Small dome-shaped papules on the face	Cosmetics; in multiple cases - search for signs of tuberous sclerosis and choose a gentle treatment [5]
Juvenile nasopharyngeal angiofibroma (JNA)	Almost always boys 10-20 years old	Nasal congestion, recurrent epistaxis, “volumetric” process on MRI/CT	Endoscopic resection, usually after embolization; observation for recurrence [6]

Epidemiology

Cutaneous angiofibromas are common benign dermatoses. A single "fibrous papule" of the face is common in young adults and remains stable for years. In tuberous sclerosis, facial angiofibromas occur in most patients and are an important clinical feature; in the non-tuberous sclerosis population, multiple lesions are rare. [7]

JNA is a rare tumor: it accounts for approximately 0.05-0.5% of all head and neck tumors, but in adolescent boys it is one of the "classic" findings of ENT oncology. The disease is almost exclusively male and typically presents between the ages of 10 and 20. Recurrences after treatment have been described in up to 30-40% of series, most often within the first 1-3 years, necessitating long-term follow-up. [8]

Modern surgery using endoscopic approaches and preoperative embolization has significantly reduced blood loss and the rate of reoperations. Meta-analyses indicate that the endoscopic approach is associated with lower recurrence compared to open approaches at comparable stages. [9]

Facial angiofibromas in patients with tuberous sclerosis are successfully controlled with topical mTOR inhibitors (sirolimus): in recent years, randomized trials have been published demonstrating papule reduction and improved appearance with a good safety profile. This has transformed patients' quality of life. [10]

Reasons

Cutaneous angiofibromas are benign proliferations of fibroblasts/dermal dendrocytes and vessels. Solitary fibrous papules are sporadic; multiple facial angiofibromas are associated with TSC1/TSC2 mutations in tuberous sclerosis, where hyperactivation of the mTOR pathway stimulates the growth of cutaneous lesions. This explains the efficacy of topical mTOR inhibitors. [11]

JNA arises in the pterygopalatine fossa/nasopharynx area and is supplied by branches of the internal and external carotid arteries (most commonly the pterygopalatine artery). These tumors are richly vascularized and grow expansively, penetrating into adjacent spaces. Hormonal theories (androgen receptors) have been discussed historically, but the practical value of antiandrogens in treatment is limited. Surgical technique and vascular control are crucial. [12]

Factors "similar" to the cause (e.g., skin trauma in the area of a fibrous papule or nasal infection in JNA) do not initiate the tumor, but can aggravate symptoms: bleeding from JNA, irritation/bloody crusting on the surface of papules when rubbed. This influences the complaints and the timing of intervention. [13]

Risk factors

No specific risk factors have been identified for a single cutaneous angiofibroma: it is a common incidental finding in healthy individuals. However, multiple facial angiofibromas are a red flag for tuberous sclerosis, especially in children: such patients require a systematic evaluation (skin, neurology, kidneys, heart). [14]

The typical profile for JNA is 10-20 years of age, male gender, and sometimes a family history. Adolescent growth spurt and rapid growth contribute to symptoms—congestion, nosebleeds, and deformity. Early referral to an otolaryngologist and radiologist shortens the path to diagnosis. [15]

Recurrence of JNA is more common in patients with more advanced stages and deep space involvement. According to series and reviews, the vast majority of recurrences occur in the first year or three, so it is during this period that monitoring (examinations/MRI) is particularly rigorous. [16]

Pathogenesis

Cutaneous angiofibromas consist of ordered collagen bundles, fibroblasts, and dilated superficial dermal vessels. In tuberous sclerosis, mTOR hyperactivation leads to fibroblast hyperplasia/angiogenesis, hence the effect of topical sirolimus (mTOR inhibition, reducing lesions). [17]

JNA is a highly vascular fibrous mass originating from the pterygopalatine fossa/nasopharyngeal vault. The classic Holman-Miller sign on CT/MRI is an anterior curvature of the posterior wall of the maxillary sinus due to tumor pressure from the pterygopalatine fossa. An important pathomechanism is the rich arterial blood supply with numerous collaterals, which explains the high blood loss during "unprepared" surgery and the benefit of embolization. [18]

The tumor is benign, but behaves "locally aggressively": it destroys bone with pressure and invades sinus tracts. Metastases are uncommon; the risk to life is associated with blood loss and intraoperative complications in advanced stages. [19]

Symptoms

Cutaneous angiofibromas: small, dome-shaped, flesh-colored pink papules (usually 1-5 mm), most often on the nose and cheeks. Single angiofibromas are considered cosmetic; they are painless, non-itchy, and grow very slowly. Multiple, symmetrical angiofibromas on the nasolabial folds in a child/adolescent should rule out tuberous sclerosis. [20]

JNA: the classic triad is nasal congestion, recurrent nosebleeds, and a nasopharyngeal mass on imaging. Nasal speech, decreased sense of smell, unilateral sinusitis, and facial pain are possible. As the disease grows, facial deformation, widening of the nasal passages, and headaches occur; with orbital extension, diplopia/exophthalmos occurs. [21]

The rate of symptom progression in JNA varies: some patients experience mild congestion and occasional bleeding for a long time, while others present with a massive tumor. Any adolescent boy with recurrent epistaxis and unilateral nasal obstruction is an indication for urgent imaging. [22]

Classification, forms and stages

Cutaneous angiofibromas are divided into solitary fibrous papules and multiple facial angiofibromas (in tuberous sclerosis). This helps decide whether cosmetic removal is sufficient or whether systemic screening and long-term monitoring are necessary. [23]

Several staging systems are used for JNA; the most well-known are the Radkowski and Fisch/Andrews-Fisch systems (grading by local spread: nasopharynx → sinuses → pterygopalatine fossa/pterygoid processes → intracranial regions). The stage determines the approach (endoscopic vs. combined/open), the need for embolization, and the prognosis of recurrence. [24]

Table 2. Stages of the JNA (very briefly)

System	Low stages	Advanced stages	Practical meaning
Radkowski	Nasopharyngeal/sinus restriction	Exit into the pterygopalatine fossa, base of the skull, intracranial	The higher the stage, the more difficult the access and the higher the risk of blood loss/recurrence [25]
Andrews-Fisch	Nose/sinuses	Pterygopalatine fossa → infratemporal/cos intracranial.	Helps plan endoscopic vs open resection [26]

Complications and consequences

Cutaneous angiofibromas themselves are not dangerous; complications are associated with trauma (abrasions, crusting) and unsuccessful removal (scarring/depigmentation). In tuberous sclerosis, the cosmetic and psychosocial effects are significant; regular therapy (topical sirolimus, lasers) improves appearance and quality of life. [27]

The main risks of JNA are blood loss and recurrence. Without preoperative embolization, intraoperative bleeding is significant; modern series demonstrate the benefit of endoscopic techniques and vascular control. Recurrences usually appear in the first 12-36 months, so long-term follow-up (examinations/MRI) is necessary. [28]

Large JNAs can deform the facial skeleton, involve the orbit and cranial base, which increases the technological complexity of surgery and the risk of neurological/ophthalmological consequences. Therefore, early detection in the "typical" patient is critical. [29]

When to see a doctor

Immediately – if a teenage boy has repeated nosebleeds and unilateral nasal congestion. This is a "red flag" for JNA → ENT examination and contrast CT/MRI. A tumor biopsy should not be performed before imaging due to the risk of severe bleeding. [30]

In the near future - if a child develops multiple symmetrical facial papules (especially in conjunction with hypomelanotic "leaflet spots," a history of seizures, or learning disabilities), this should be considered to rule out tuberous sclerosis and discuss treatment for facial angiofibromas. [31]

Planned treatment for a single papule on the nose/cheek that is cosmetically unsightly: a dermatologist will confirm the diagnosis (dermatoscopy ± shave biopsy) and recommend a gentle removal. The risk of recurrence after complete removal is minimal. [32]

Diagnostics

Cutaneous angiofibromas. Step 1: Clinical presentation and dermatoscopy (homogeneous pink-yellowish papule with superficial vessels). Step 2: If in doubt, perform a shave biopsy: removal + histology. Step 3: If a child has multiple facial lesions, screen for tuberous sclerosis (anamnesis, skin examination, neurology, ultrasound/MRI of the kidneys, etc., according to standards). [33]

JUNIOR. Step 1 - Clinical presentation: adolescent boy, bleeding and congestion. Step 2 - CT/MRI with contrast: large, intensely contrast-enhancing mass in the nasopharynx; important features - extent and Holman-Miller sign (anterior curvature of the posterior wall of the maxillary sinus). Step 3 - Angiography for embolization planning. Biopsy before visualization is contraindicated. [34]

Staging of JNA. Radkowski/Andrews-Fish, using CT/MRI data, determines the surgical strategy. Low stages are candidates for purely endoscopic resection; for more extensive ones, combined approaches are recommended, sometimes followed by radiation therapy for unresectable remnants. [35]

Table 3. Visualization for JNA: what we are looking for

Method	What does it show?	How it helps
Contrast CT	Bone changes, Holman-Miller sign	Planning access/resection volume [36]
MRI with contrast	Soft tissue component, space distribution	Assessment of skull boundaries/base [37]
Angiography	Sources of blood supply	Preoperative embolization [38]

Differential diagnosis

Cutaneous angiofibromas are distinguished from intradermal nevus, seborrheic keratosis, molluscum contagiosum, and early basal cell carcinoma. Dermoscopy and shave biopsy are usually definitive; fibrous papules rarely recur after removal. [39]

JNA must be differentiated from polyps/chronic sinusitis (less vascular, no aggressive bone remodeling), angiofibromas of other sites, rhabdomyosarcoma, and rare vascular tumors. Clues to JNA include a teenage boy, epistaxis, intense contrast, Holman-Miller sign, and pronounced arterial nutrition on angiography. [40]

Treatment

Solitary cutaneous angiofibromas are treated for cosmetic reasons. The best methods are shave excision or electrosurgery/radiofrequency; cryotherapy and lasers (ablative and vascular) are also possible. The specimen is sent for histology. Recurrence is rare, and outcomes are generally excellent. [41]

For multiple facial angiofibromas (especially in the setting of tuberous sclerosis), topical mTOR inhibitors (sirolimus/rapamycin) have become the mainstay. Randomized trials and systematic reviews have demonstrated a clinically significant reduction in the number/height of papules, redness, and bleeding with a good safety profile; they are used long-term. If necessary, lasers (pulsed-dye, CO2, fractional) are added for texture and vascularity. [42]

Systemic mTOR inhibitors are prescribed for tuberous sclerosis (renal angiomyolipoma, epilepsy, etc.). They also affect the skin, but the decision is made by a specialized team, taking into account the systemic effects and treatment goals. Cosmetic ablations without control of the underlying disease provide short-term results. [43]

JNA is treated surgically. Endoscopic endonasal resection is currently considered a first-line approach for most stages without massive intracranial growth. According to meta-analyses and reviews, endoscopy is associated with less blood loss and a lower recurrence rate than open approaches at comparable stages, especially if preoperative embolization of feeding vessels is performed 24-72 hours before surgery. [44]

Preoperative embolization (often with particles/glues through branches of the external carotid artery) reduces intraoperative blood loss and operative time. Some centers report procedures without embolization, but most guidelines recommend it when high vascularity/volume is expected. The decision depends on the angioarchitecture and the experience of the team. [45]

Radiation therapy is considered for unresectable remnants or recurrences, particularly in cases of intracranial extension when complete, safe resection is not possible. It reduces tumor volume and controls bleeding, but in the pediatric population, its use is cautious (considering long-term risks). [46]

Pharmacotherapy for JNA is limited. Antiandrogens and antiangiogenic approaches have historically been tried; there is no convincing randomized evidence for routine use. In rare situations (multiple recurrences, unresectable remnants), individualized solutions may be possible within a multidisciplinary consultation. Surgery and embolization remain the mainstays of treatment. [47]

Intra- and postoperative management includes anemia correction, infection prevention, pain control, gentle packing, and early imaging in cases of atypical progression. Signs of recurrence are explained to parents/patients: recurrence of nosebleeds, new congestion, headaches. Most recurrences are detected within the first 12 months. [48]

Post-operative follow-up: ENT examinations, nasal endoscopy, and follow-up MRI (usually annually for the first 3-4 years, then as clinically indicated), as up to 1/3 of recurrences occur after the initial surgery. If in doubt, early repeat endoscopy/MRI is preferable. [49]

Cosmetic and psychosocial aspects. For facial angiofibromas, selection of a long-term regimen (topical sirolimus ± laser) and photoprotection are critical. For JNA, family support, explanation of the benign nature and the need for monitoring reduce anxiety. Both groups benefit from photographic documentation and surveillance plans. [50]

Table 4. Treatment: who and what is the “first choice”

Situation	First line	Alternatives/additions
Solitary cutaneous angiofibroma	Shave excision/electrosurgery	Cryo/lasers; histology is mandatory if in doubt [51]
Multiple facial angiofibromas (MFA)	Long-term topical sirolimus	Lasers (PDL, CO2, fractional), systemic mTOR according to TCC indications [52]
Low/moderate stage JNA	Endoscopic resection + embolization	- [53]
JNA with extension to the base of the skull	Combined approaches ± radiation therapy	Individual multi-team solutions [54]

Table 5. Topical options for facial angiofibromas (FA)

Means	Data	Comment
Sirolimus (rapamycin) cream/gel	RCTs/reviews: reduction in height/erythema, good safety profile	Long-term use, maintenance treatment is necessary [55]
Lasers (PDL, CO₂, fractional)	Case series, good cosmetic outcomes	Often combined with sirolimus; repeat sessions are needed [56]

Table 6. JNA: the role of embolization and endoscopy

Question	Practice	What the data shows
Does everyone need embolization?	Recommended for severe vascularity/volume	Reduces blood loss and operative time; the approach depends on the angioarchitecture and experience of the center [57]
Endoscopy vs. open surgery	Endoscopy is the standard in most stages	Lower risk of recurrence/blood loss at comparable stages (meta-analyses) [58]

Prevention

Solitary cutaneous angiofibromas cannot be prevented—they are "accidental" dermatological conditions. To avoid damaging the papules, avoid rubbing and aggressive peeling of the affected area; if desired, consider scheduled, gentle removal. [59]

For tuberous sclerosis, regular skin care (sun protection, gentle cosmetics) and maintenance topical sirolimus help control facial angiofibromas and reduce the frequency of "under-bleeding." Keratinization flare-ups are corrected with laser treatments. [60]

There is no prevention for JNA; early recognition works: adolescent boy + epistaxis + congestion → ENT + imaging. Awareness among primary care physicians and parents is key to timely referral. [61]

Forecast

Cutaneous angiofibromas have an excellent prognosis: recurrence is rare after complete removal of a single fibrous papule, and in tuberous sclerosis, long-term topical therapy significantly improves appearance. Quality of life improves within 4-12 weeks of starting topical sirolimus. [62]

JNA is a benign but recurrent tumor: after modern endoscopic resection with embolization, control is achievable in most cases; however, observation for at least 3-4 years is necessary, as up to 30-40% of relapses occur during this period (most often in the first year). Repeat endoscopic resections are successful in many cases. [63]

FAQ

Is a fibrous papule on the nose a "tumor"? Should it be removed?
It's a benign cutaneous angiofibroma. Removal is cosmetic (shave excision/electrosurgery/laser); the tissue is sent for histology. Recurrence is rare. [64]

A child has developed symmetrical papules on the nasolabial folds. What should I do?
See a dermatologist: multiple facial angiofibromas are a hallmark of tuberous sclerosis. Current treatment options include topical sirolimus and lasers. [65]

A teenager with frequent nosebleeds and congestion. Is this dangerous?
Juvenile nasal congestion should be ruled out: get a CT/MRI with contrast and consult an ENT oncologist. If confirmed, perform endoscopic resection, often followed by embolization. [66]

Is it possible to treat JNA "without surgery"?
The standard is surgery. Radiation therapy/drug approaches are options for residual/recurrent or unresectable disease and are decided upon in consultation. [67]

What is the risk of recurrence of JNA?
According to series and reviews, it is approximately 30-40% overall, with a peak in the first 12-36 months, requiring routine monitoring. An endoscopic approach is associated with a lower recurrence rate at comparable stages. [68]